Sotatercept, a novel, first-in-class fusion protein therapy, significantly improved pulmonary-vascular, cardiovascular, and exercise-related outcomes in patients with pulmonary arterial hypertension (PAH) at 24 weeks, according to findings from the PULSAR trial.

As the medical director of the Medical Intensive Care Unit at Denver Health, Dr. Ivor Douglas knows better than most how devastating a toll COVID-19 has taken. “We’ve lost 400,000 people, which is as many Americans as were lost in the Second World War,” he says. (The number topped 520,000 in early March.) “And we’ve done it in a year.”

When the only doctor who could possibly cure her son wouldn’t return her messages, Amber Freed sent daily snack deliveries to his office. That earned her a call—but a brief one: Dr. Steven Gray, a Dallas physician who specializes in gene therapy, couldn’t talk long because he was on his way out the door to a conference in Atlanta.

Lung cancer is the deadliest form of the disease, though radiologists can help catch this concern with proper screening using low-dose CT. Only 46% of patients actually stick to their annual exam schedule, however, with a few factors proving predictive, experts detailed on Tuesday.